Ev3, Inc. was founded with the goal of building a "middle-market" alternative to its diversified, multi-billion dollar competitors in the $10 billion market for endovascular devices. Completing five acquisitions and three strategic partnerships since mid-2000, ev3 has demonstrated that a company can be large enough to support global distribution and market development without sacrificing responsiveness to technologies that address unmet or underserved clinical needs. ev3 has established positions in emerging endovascular technologies such as embolic protection, thrombectomy, stroke prevention, carotid artery stenting, and cerebral aneurysm repair. ev3 (NASDAQ: EVVV) completed its Initial Public Offering in June, 2005.
ev3 has filed 35 patents.
Interventional radiology, Catheters, Endoscopy, Surgical procedures and techniques, Implants (medicine)
Interventional radiology, Catheters, Endoscopy, Surgical procedures and techniques, Implants (medicine)
Latest ev3 News
Nov 18, 2023
- The EV revolution continues: EV3 and EV4 concept models illustrate the evolution of Kias Opposites United design philosophy - Concept EV3 crossover debuts: Introducing exceptional practicality and a transformative cabin ambience, with influence from the flagship EV9 - Concept EV4: Innovative four-door typology meets next-generation materiality in the post-sedan era LOS ANGELES, Calif. – WEBWIRE – Friday, November 17, 2023 Today, Kia America introduced the all-electric EV3 and EV4 concept models at the 2023 Los Angeles Auto Show. Showcasing Kias cutting-edge electric platform technology, styling derived from the tenets of the Opposites United design philosophy, and a commitment to a leading color, material, and finish (CMF) strategy, the Concept EV3 and Concept EV4 represent contrasting vehicle typologies with a common thread. Like other Kia design studies, the Concept EV3 and Concept EV4 offer visions of potential future products. The Concept EV3 and Concept EV4 are sharply styled, material-driven concepts that point to the expansion of the Kia EV lineup, and California is the barometer for successful EVs, said Steven Center, COO & EVP, Kia America. Thats why we came to Los Angeles and Americas savviest EV consumers, to gauge reaction to two potential opportunities within the Kia lineup. Earlier this year, at the launch of the EV9 flagship electric SUV in March, Kia introduced 10 must-have items that it would like to use in new Kia models including the Concept EV3 and Concept EV4. The materials include bioplastic, produced from biomass sources such as vegetable oils, corn extract, sawdust and sugarcane, and Bio Polyurethane as a replacement for animal-based leather. The Concept EV3: Distilling the essence of the EV9 to the compact segment and providing technology, practicality and design The Concept EV3 represents the brands vision for an electric, compact crossover that offers the technology, practicality, and design of Kias flagship SUV, the EV9. The Concept EV3 features a high degree of inspiration from the Joy for Reason pillar of the Opposites United design philosophy. With the Concept EV3, the Joy for Reason influence is evident in the contrasting qualities of a robust body combined with a dynamic silhouette, said Karim Habib, Executive Vice President and Head of Kia Global Design Center. In addition, the unexpected treatment of volumes and graphics simultaneously interlock with each other, creating a logical yet emotional design. The design treatment of the Concept EV3s exterior creates a unique silhouette, with the windshield pushed forward, a sloping roofline, and a disconnected C pillar that links the glasshouse surfaces and gives the roof a floating effect. The robust exterior architecture of the squared wheel arches, cut with asymmetrical angles, results in an unexpected logic and a strong impression. Inside, the Concept EV3 blends exceptional practicality with transformative cabin ambience and design. The interior of the Concept EV3 creates an expansive visual sense, providing an environment that promotes emotional wellbeing, enhanced by soft mood lighting and ultra-clean dashboard surfacing. Advanced ergonomic seat design comprises natural fiber structures to deliver a lightweight, slimmer seat design. The exceptionally strong, fiber weave enables more elegant, modern aesthetics, complemented by soothing natural tones. For the seat covers, the CMF team applied 3D Knit technology. These materials combine with tables that slide forward and backward and can support four modes: Focus, Social, Refreshing and Storage. The console table contains bio-plastic materials leveraged to create a forward-thinking solution. The Concept EV4: Redefining the essence of the electric sedan The Concept EV4 represents the purity of the Power to Progress pillar of the Opposites United design philosophy. Its four-door format emphasizes potent and impactful lines that represent an entirely new type of EV sedan that stands as a symbol of innovation. Brought to life through a harmonious fusion of confident, geometric diagonal character lines and rich yet technical surfaces, the Concept EV4 represents a new value, approach, customer experience, and typology. Its exterior form factor incorporates attributes reminiscent of sports and racing cars, including a low nose, a long-tail silhouette, and a technical roof spoiler. Featuring a wide, imposing stance, with headlamps located vertically at the extreme outer edges of the hood and front bumper, the Concept EV4 further symbolizes Kias determination to push design boundaries. The cocoonlike interior of the Concept EV4 features a sleek and spacious horizontal layout. The innovative design of the HVAC user interface incorporates a control panel that can be neatly stored in the center console when not in use and applied pin-style air vents that offer the flexibility to change patterns. Handwoven fabric stripes applied to the vehicles storage area and dashboard create a 3D effect. Materiality also looms large in the interior of the Concept EV4 through the implementation of natural dyes and recycled cotton. Kia America about us Headquartered in Irvine, California, Kia America continues to top automotive quality surveys. Kia is recognized as one of the TIME100 Most Influential Companies of 2023. Kia serves as the Official Automotive Partner of the NBA and offers a range of gasoline, hybrid, plug-in hybrid and electric vehicles sold through a network of over 775 dealers in the U.S., including several cars and SUVs proudly assembled in America*. For media information, including photography, visit www.kiamedia.com . To receive custom email notifications for press releases the moment they are published, subscribe at www.kiamedia.com/us/en/newsalert . * The K5, Sportage, Sorento, and Telluride (excludes HEV and PHEV models) are assembled in the United States from U.S. and globally sourced parts. Press Release Information Accuracy DisclaimerInformation posted in press releases on the Kia Media website was accurate at the time of posting but may be superseded by subsequent releases or other information. ( Press Release Image: https://photos.webwire.com/prmedia/8/314149/314149-1.jpg )
ev3 Frequently Asked Questions (FAQ)
When was ev3 founded?
ev3 was founded in 2000.
Where is ev3's headquarters?
ev3's headquarters is located at 9600 54th Avenue North, Plymouth.
What is ev3's latest funding round?
ev3's latest funding round is Acq - P2P.
Who are the investors of ev3?
Investors of ev3 include Covidien, Warburg Pincus and The Vertical Group.
Who are ev3's competitors?
Competitors of ev3 include OrthAlign, Tornier, Anteis, Cameron Health, Embrella Cardiovascular and 7 more.
Compare ev3 to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Navis is a Cleveland, Ohio based company that has developed the Variable Control Guidewire System, a guidewire technology that aims to improve endovascular navigation and eliminate or reduce the need for multiple catheters and guidewires required during invasive peripheral vascular procedures.
Avertix develops an implantable cardiac monitoring and alerting system to warn cardiac patients of potentially life-threatening heart conditions. It offers heart monitors that track changes in the heart's electrical signal from a pacemaker lead. It identifies the symptoms of acute thrombotic occlusions by alerting the patient to seek medical attention. The firm was formerly known as Angel Medical Systems and changed its name to Avertix in April 2023. The company was founded in 2001 and is based in Eatontown, New Jersey.
Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures. Acquired by Boston Scientific in 2001.
Es Vascular is a company focused on the medical industry, specifically in the distribution of medical supplies. The company offers a range of products including medical devices for urology, surgery, anesthesiology, tissue regeneration, wound management, biopsy needles, and gynecology. These products are designed to treat various medical conditions and assist in different medical procedures. It was founded in 2000 and is based in Israel.